

**17 November 2021**

Australian Securities Exchange  
20 Bridge Street,  
Sydney NSW 2000

## **Annual General Meeting – Chair Address**

I'm very pleased to be providing you with my address following a year of great achievement for Alcidion. Two years ago, the Board agreed on a three-year growth plan that would move us from digital health aspirant to a global organisation at the frontier of unlocking and managing data, to benefit clinicians and improve healthcare outcomes. We are seeing a significant step change where technology is transforming healthcare by streamlining the hospital workflow, optimising legacy systems, reducing human error, and responding to patient desire for out of hospital care.

This step change has in part been driven by the very thing that keeps us apart today with smart and efficient healthcare systems equipping hospitals with greater resilience and an ability to cope with surges in demand – like we've seen with Covid - with reduced impact on patient care.

Our flagship product Miya Precision is powerful in its utility to provide this solution, and it was pleasing to see growing demand over this last 12 months. Most significantly was our milestone deal with South Tees Hospitals in the UK, and our selection as preferred provider with the Australia Department of Defence.

We are trusted by some of the world's leading healthcare organisations in Australia, New Zealand, and the United Kingdom with our share of customer increasing in each of these markets. The impact of our growth strategy was compelling, with record revenue, positive operating cash flow, and growing momentum in new contracts. This combined with retention of existing customers provides a strong foundation for continued growth in the years to come.

Given the focus on digital health solutions to address the myriad of challenges within hospitals, our active M&A program sought to continuously assess and identify potential acquisition targets. This has been a highly disciplined process where acquisitions could enable us to expand our team, our product capabilities, our market presence, and align with our current product suite. Our acquisition of UK patient flow software business ExtraMed achieved all these, building on our current flow products and expanding our UK footprint with new customers and staff.

Aligned with our growth strategy, we have as a board adopted a forward-thinking and continuous approach to evaluating the skills and experience of the Board to support Alcidion's next phase of growth. As part of this program, Alcidion co-founder and former CEO Ray Blight retired from the Board in June and Nick Dignam concludes his 5-year board tenure today.

I'd like to take the opportunity to thank Ray for his exceptional contribution to the success of Alcidion both as a company executive and then non-executive director, and Nick for his guidance and leadership, particularly in his capacity as Chair of the Audit and Risk Committee and his guidance on our acquisition program.

The rotation of these directors allowed us to attract and appoint two highly regarded Non-Executive directors - Victoria Weekes and Daniel Sharp - to steer our company in this next phase. Welcome to you both.

Finally, the support of shareholders has enabled us to implement our growth strategy through our successful capital raising earlier this year. Whilst we are pleased to see our business self-generating cash flow, additional funding is enabling us to fast track our growth. This continued investment will enable us to achieve greater economies of scale and capitalise on the opportunities ahead of us.

Ultimately our success is measured through the positive influence our technology has on patient care - we started our company with this purpose, and it informs our work at every level within Alcidion. Today we have more than 150 staff and I'd like to thank them all, for our success is the sum of what they do each day. I'd also like to thank Kate and her Senior Leadership Team, my fellow Directors, and you, our shareholders.

Thank you.

-- ENDS --

Authorised for ASX release by the Board of Directors of Alcidion Group Limited.

For further information, please contact:

**Hannah Howlett**

WE Communications

Ph: +61 450 603 182

[hhowlett@we-worldwide.com](mailto:hhowlett@we-worldwide.com)

**About Alcidion Group Limited (ASX:ALC)**

Alcidion Group Limited (Alcidion) has a simple purpose: to transform healthcare with proactive, smart, intuitive technology solutions that improve the efficiency and quality of patient care in healthcare organisations, worldwide.

Alcidion offers a complementary set of software products and technical services that create a unique offering in the global healthcare market. Based on the flagship product, Miya Precision, the solutions aggregate meaningful information to centralised dashboards, support interoperability, facilitate communication and task management in clinical and operational settings and deliver Clinical Decision Support at the point of care; all in support of Alcidion's mission to improve patient outcomes.

Since listing on the ASX in 2011, Alcidion has acquired multiple healthcare IT companies and expanded its foothold in the UK, Australia, and New Zealand to now service over 300 hospitals and 60 healthcare organisations, with further geographical expansion planned.

With over 20 years of healthcare experience, Alcidion brings together the very best in technology and market knowledge to deliver solutions that make healthcare better for everyone.

[www.alcidion.com](http://www.alcidion.com)

© Alcidion Group Limited 2021. Alcidion, Miya Precision, Patientrack and Smartpage are registered trademarks. All other brands and product names and trademarks are the registered property of their respective companies.